Anthony Rodrigues, MD
Neurology with Special Qualifications in Child Neurology · Norwwod, MANPI 1740613371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 105 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $688 and has fallen 52.5% since, to $327 in 2025.
Across 105 payments — averaging $21.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SK Life Science, Inc.$520
- EMD Serono, Inc.$239
- AbbVie$178
- UCB, Inc.$113
- Medtronic$105
- Genentech USA, Inc.$89
- plus $986 from 33 others
What the payments were for
- Food & beverage$2,222100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SK Life Science, Inc. | 17 | $520 |
| EMD Serono, Inc. | 9 | $239 |
| AbbVie(2 entities) | 8 | $178 |
| UCB, Inc. | 5 | $113 |
| Medtronic(2 entities) | 4 | $105 |
| Genentech USA, Inc. | 4 | $89 |
| Acadia Pharmaceuticals Inc | 4 | $78 |
| Amneal Pharmaceuticals LLC | 5 | $71 |
| Averitas Pharma Inc. | 3 | $64 |
| Catalyst Pharmaceuticals, Inc. | 3 | $64 |
| Neuropace, Inc. | 3 | $58 |
| Bristol Myers Squibb | 3 | $54 |
| GRT US Holding, Inc. | 2 | $41 |
| Ipsen Biopharmaceuticals, Inc | 2 | $39 |
| Insightec,inc | 2 | $38 |
| Greenwich Biosciences, Inc. | 2 | $34 |
| Cycle Pharmaceuticals Inc | 2 | $30 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Argenx US, Inc. | 1 | $27 |
| CSL Behring | 1 | $27 |
| Livanova USA, Inc. | 2 | $26 |
| Sunovion Pharmaceuticals Inc. | 1 | $24 |
| Biogen | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| AstraZeneca | 1 | $19 |
| MDD US Operations, LLC | 1 | $18 |
| Grifols USA, LLC | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Pfizer | 1 | $15 |
| Mylan Specialty L.p. | 1 | $14 |
| Neurelis, Inc. | 1 | $14 |
| Eisai Inc. | 1 | $14 |
| Alnylam Pharmaceuticals Inc. | 1 | $14 |
| Lilly USA, LLC | 1 | $13 |
| Life Molecular Imaging Ltd | 1 | $12 |
| Travere Therapeutics, Inc. | 4 | $7 |
How this compares
$2,230 in reported general payments places this provider in the 80th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
See all neurology with special qualifications in child neurology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpidiolexCannabidiol (Cbd) | 55 | $235,006 |
| BotoxOnabotulinumtoxina | 15 | $31,071 |
| OnfiClobazam | 12 | $24,476 |
| Baclofen | 37 | $5,856 |
| Levetiracetam | 48 | $4,160 |
| Lamotrigine | 28 | $1,272 |
| Hydroxyzine Hcl | 14 | $430 |
| Phenytoin | 12 | $429 |
| Gabapentin | 13 | $235 |
| Phenobarbital | 14 | $232 |
| Tizanidine Hcl | 11 | $162 |
| Clonazepam | 27 | $100 |
| Lorazepam | 20 | $74 |
| Alprazolam | 16 | $38 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox | $178 | $31,07115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 101 neurology with special qualifications in child neurology providers in Massachusetts.
Other neurology with special qualifications in child neurology in Norwwod
- Elizabeth ThieleBoston$278K
- Jurriaan PetersBoston$265K
- Basil DarrasBoston$253K
- Kiran MaskiBoston$105K
- Phillip PearlBoston$50K
- Paul ChervinWoburn$36K
- Alexander RotenbergBoston$34K
- Irina AnselmBoston$30K
- Nicole UllrichBoston$26K
- David LiebermanBoston$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.